华夏中证500指数增强A（007994）成立日期2020年3月25日，最新规模31.35亿。今年以来收益 22.68%，同类排名2087/4218；近一年收益26.47%，同类排名1691/3868；成立以来收益126.35%。 华夏中证500指数增强A（007994）基金经理为孙蒙。 截至发稿，孙蒙累计任职时间5年220天，现任基金资产总规模104.61亿元，任职期间最佳基金回报 126.46%， 任职期间最差基金回报17.83%。 10月21日，洁特生物涨5.45%，截至发稿，报19.14元/股，成交3647.27万元，换手率1.40%，总市值 26.87亿元。 资料显示，广州洁特生物过滤股份有限公司位于广东省广州经济技术开发区永和经济区斗塘路1号，成 立日期2001年4月11日，上市日期2020年1月22日，公司主营业务涉及细胞培养类及与之相关的液体处理 类生物实验室一次性塑料耗材研发、生产和销售。主营业务收入构成为：液体处理类60.24%，生物培 养类30.74%，其他(补充)4.98%，仪器设备及其他类4.04%。 从洁特生物十大流通股东角度 数据显示，华夏基金旗下1只基金位居洁特生物十大流通股东。 ...

1、海外市场：以ODM 为基础，加速自主品牌输出 公司以ODM 模式切入全球生物实验室耗材供应链，凭借自主设计与制造能力，与VWR、Thermo Fisher 等国际龙头建立稳定合作，产品远销欧美等70 多个国家及地区，逐步在海外市场建立了"质量可 靠"和"性价比突出"的形象。随着产品质量逐渐被欧美客户认可，公司发力自主品牌，以高品质的产 品、优质的服务和更划算的价格拓展市场，2024 年公司在欧洲、南美、东南亚等区域市场的自主品牌 渗透率显著提升，海外自主品牌收入同比增加46.07%，在境外收入占比达18.89%。我们认为随着公司 海外自主品牌推广战略逐步落地，公司有望实现从代工生产到自主品牌的转型升级，在国际实验室耗材 供应链中获得更多的价值量。 2、国内市场：把握进口替代机会，科研市场+工业市场齐发力 在当前国际贸易局势下，国家在卡脖子领域强调要提升自主可控的能力，生命科学实验室耗材国产化率 有望加速提升。洁特生物作为国内最早生产生物实验室一次性塑料耗材的企业之一，具有较强的先发优 势，营收规模位于行业领先位置。在国产替代的背景下，公司一方面扩大销售网络覆盖面，2024年在国 内设12 个办事处，提升了 ...

Investment Rating - The investment rating for the company is "Buy" [2] Core Views - The report highlights that the company has over 20 years of experience in the biological laboratory consumables sector, focusing on biological culture and liquid handling, with leading technical strength and a comprehensive product matrix. The company is expected to maintain rapid growth as its influence in overseas markets increases and both domestic industrial and research markets expand [3][4][5] Summary by Sections 1. Overseas Market - The company has entered the global biological laboratory consumables supply chain through an ODM model, establishing stable partnerships with international leaders like VWR and Thermo Fisher. The company has built a reputation for "reliable quality" and "outstanding cost performance," with overseas self-brand revenue increasing by 46.07% year-on-year in 2024, accounting for 18.89% of total revenue [4][14] 2. Domestic Market - The company is well-positioned to capitalize on the opportunity for import substitution in the current international trade climate. As one of the earliest producers of disposable plastic consumables in China, the company is expanding its sales network and has established 12 offices domestically in 2024. The sales of its cell factory products are expected to grow by approximately 28.55% year-on-year [5][49][53] 3. Product High-Endization and Smart Manufacturing - The company is focused on developing high-end products such as liquid culture media and cell culture bags while optimizing production processes to reduce manufacturing costs. The establishment of an intelligent manufacturing base is expected to enhance order delivery efficiency and support global business needs [6][15] 4. Financial Forecast and Investment Recommendation - The company is projected to achieve revenues of 652 million yuan, 772 million yuan, and 919 million yuan from 2025 to 2027, with year-on-year growth rates of 16.7%, 18.3%, and 19.1% respectively. The net profit attributable to the parent company is expected to be 98 million yuan, 118 million yuan, and 145 million yuan during the same period, with corresponding growth rates of 35.3%, 20.6%, and 23.2% [6][8][20]

Core Viewpoint - The credit rating agency has assigned a stable outlook to Guangzhou Jiete Biological Filtration Co., Ltd., reflecting its solid operational foundation and stable cooperation with global life science industry leaders, despite facing certain risks related to capacity digestion and reliance on overseas clients [3][6][16]. Company Overview - Guangzhou Jiete Biological Filtration Co., Ltd. specializes in the research, production, and sales of cell culture and related liquid handling life science consumables, maintaining a strong R&D capability in the field [3][5]. - The company has a credit rating of A+ with a stable outlook, indicating a good financial position and manageable debt levels [3][6]. Financial Performance - As of March 2025, the company's total assets reached 17.05 billion, with equity attributable to shareholders at 12.06 billion and total debt at 3.70 billion [3][4]. - The company's revenue for 2024 was 5.59 billion, with a net profit of 0.73 billion, showing a recovery in both revenue and profit scales [3][4]. - The cash-to-short-term debt ratio was notably high at 104.08, indicating strong liquidity [4][5]. Market Position - The company holds a significant position in the domestic supply chain for biological laboratory consumables, with stable cooperation with high-quality clients [6][9]. - The global life science industry giants continue to be major clients, ensuring a steady revenue stream [6][16]. Industry Environment - The life science industry in China has seen rapid growth in research funding, increasing from 59.7 billion in 2017 to 141.5 billion in 2023, with a compound annual growth rate of 15.5% [9][10]. - The market for biological laboratory consumables is projected to grow from 16.49 billion in 2022 to 23.42 billion in 2024, with a compound annual growth rate of 19.17% [10][11]. Risks and Challenges - The company faces uncertainties in capacity digestion and is highly dependent on overseas clients, with 66.13% of its revenue coming from international sales [5][16]. - The reliance on imported raw materials poses risks related to price fluctuations and geopolitical factors, which could adversely affect the company's performance [5][16]. Future Outlook - The credit rating agency maintains a stable outlook for the company, citing its strong cash position and low debt levels as positive indicators for future performance [6][9]. - The company is expected to continue benefiting from its established relationships with global life science leaders, although it must navigate the challenges posed by market competition and external economic factors [6][16].